These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 37343141)

  • 21. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Jung C; Park S; Kim H
    PLoS One; 2023; 18(11):e0294423. PubMed ID: 37992029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis.
    Ding C; Tang Y; Zhu W; Huang P; Lian P; Ran J; Huang X
    Acta Diabetol; 2022 Apr; 59(4):519-533. PubMed ID: 34988690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
    Patoulias D
    Acta Medica (Hradec Kralove); 2017; 60(4):167-170. PubMed ID: 29716685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.
    Yan H; Huang C; Shen X; Li J; Zhou S; Li W
    Front Endocrinol (Lausanne); 2022; 13():923606. PubMed ID: 35909522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis.
    Ong Lopez AMC; Pajimna JAT
    Sci Rep; 2024 Jan; 14(1):2122. PubMed ID: 38267513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
    Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
    J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials.
    Gu Y; Sun L; Zhang W; Kong T; Zhou R; He Y; Deng C; Yang L; Kong J; Chen Y; Shi J; Hu Y
    Front Pharmacol; 2023; 14():1102792. PubMed ID: 36992825
    [No Abstract]   [Full Text] [Related]  

  • 32. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
    Cho KY; Nakamura A; Omori K; Takase T; Miya A; Yamamoto K; Nomoto H; Kameda H; Taneda S; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Jul; 12(7):1272-1277. PubMed ID: 33131199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Zou H; Liu L; Guo J; Wang H; Liu S; Xing Y; Deng C; Xiao Y; Zhou Z
    J Diabetes Investig; 2021 Apr; 12(4):546-556. PubMed ID: 33245620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes].
    Røder ME; Storgaard H; Rungby J; Knop FK; Vilsbøll T
    Ugeskr Laeger; 2016 Sep; 178(38):. PubMed ID: 27649712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study.
    Guo W; Zhao L; Huang W; Chen J; Zhong T; Yan S; Hu W; Zeng F; Peng C; Yan H
    Cardiovasc Diabetol; 2024 Apr; 23(1):118. PubMed ID: 38566143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus.
    Fujimori N; Tanaka N; Kimura T; Sano K; Horiuchi A; Kato N; Takahashi Y; Kuribayashi N; Sugiura A; Yamazaki T; Joshita S; Umemura T; Matsumoto A; Tanaka E
    Clin J Gastroenterol; 2020 Feb; 13(1):83-89. PubMed ID: 31292843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents.
    Kunutsor SK; Zaccardi F; Balasubramanian VG; Gillies CL; Aroda VR; Seidu S; Davies MJ; Khunti K
    Diabetes Obes Metab; 2024 May; 26(5):1837-1849. PubMed ID: 38379094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.